| Report | Options implied | Actual move | Market was |
|---|---|---|---|
| 05/06/2026 | ±4.4% | -16.4% | under-priced |
| 02/04/2026 | ±4.1% | +6.3% | under-priced |
| 11/05/2025 | ±3.4% | -1.9% | over-priced |
| 05/08/2025 | ±4.9% | +2.1% | over-priced |
| 11/05/2024 | ±4.7% | +2.3% | over-priced |
| 05/06/2024 | ±6.0% | -1.6% | over-priced |
| 02/07/2024 | ±4.6% | -1.5% | over-priced |
| 11/07/2023 | ±6.7% | +1.6% | over-priced |
| Quarter | EPS (dil.) | Revenue | Net income |
|---|---|---|---|
| Q4 FY2026 | $0.35 | $321M | $55M |
| Q3 FY2026 | $0.32 | $311M | $51M |
| Q2 FY2026 | $0.24 | $296M | $38M |
| Q1 FY2026 | $0.24 | $287M | $38M |
Bio-Techne Corp. (TECH) reports in 9 days, with the next report estimated for 09/21/2026. Across the last 8 reports, options priced an average ±4.8% earnings move while the stock actually moved 4.2% on average — the market has systematically over-priced TECH's earnings risk. Fundamentals into the print: EPS up 418.2% year-over-year, revenue up 1.3%. QuantLogix's live 5-factor engine currently reads TECH as a buy at 62/100.
Implied move is derived from at-the-money option pricing; actual moves are close-to-close on report days. Next-report dates are estimates until confirmed by the company. Educational market analysis, not investment advice. Browse all signal scorecards →